Sugi Predict

Sugi Predict / Compounds / Dactinomycin

Dactinomycin

Dactinomycin

SCHEMBL987923

COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cc1c2oc3c(C)ccc(C(=O)N[C@@H]4C(=O)N[C@H](C(C)C)C(=O)N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)c3nc-2c(C(=O)N[C@@H]2C(=O)N[C@H](C(C)C)C(=O)N3CCC[C@H]3C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]2C)c(N)c1=O

nearest known ligand 0.61

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

TOP2A

The experimentally established mechanism targets of Dactinomycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TOP2A known ✓ P11388 1/20 0.48
▸ GRB2 P62993 3/20 0.61
▸ MAPT P10636 3/20 0.61
▸ RECQL P46063 3/20 0.61
▸ SMN1; SMN2 Q16637 3/20 0.61
▸ KMT2A Q03164 3/20 0.61
▸ HIF1A Q16665 3/20 0.61
▸ ALDH1A1 P00352 2/20 0.61
▸ PTGS1 P23219 2/20 0.61
▸ CASP1 P29466 2/20 0.61
▸ HTT P42858 2/20 0.61
▸ BLM P54132 2/20 0.61
▸ ABCB11 O95342 1/20 0.61
▸ CYP3A4 P08684 1/20 0.61
▸ ALOX15 P16050 1/20 0.61
▸ CASP7 P55210 1/20 0.61
▸ DDR2 Q16832 1/20 0.61
▸ NGLY1 Q96IV0 1/20 0.61
▸ HSD17B10 Q99714 1/20 0.61
▸ MEN1 O00255 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dactinomycin SCHEMBL28142059 1.00 GRB2 (0.61) GRB2MAPTRECQLSMN1; SMN2KMT2A
Dactinomycin SCHEMBL4018041 0.96 RECQL (0.62) GRB2MAPTRECQLSMN1; SMN2KMT2A
Dactinomycin SCHEMBL28208187 0.96 RECQL (0.62) GRB2MAPTRECQLSMN1; SMN2KMT2A
Dactinomycin SCHEMBL27881861 0.96 RECQL (0.62) GRB2MAPTRECQLSMN1; SMN2KMT2A
Dactinomycin SCHEMBL28238143 0.91 RECQL (0.54) GRB2MAPTRECQLSMN1; SMN2KMT2A
Dactinomycin SCHEMBL28212929 0.89 MAPT (0.48) GRB2MAPTRECQLSMN1; SMN2KMT2A
Dactinomycin SCHEMBL28182665 0.85 RECQL (0.47) GRB2MAPTRECQLSMN1; SMN2KMT2A
Dactinomycin SCHEMBL28243094 0.81 MAPT (0.43) GRB2MAPTRECQLSMN1; SMN2KMT2A
Dactinomycin SCHEMBL3844 0.78 GRB2 (1.00) GRB2MAPTRECQLSMN1; SMN2KMT2A
Dactinomycin SCHEMBL6152 0.78 GRB2 (1.00) GRB2MAPTRECQLSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210348236-A1 MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN ANDES BIOTECHNOLOGIES GLOBAL INC (US) 2021-11-11 — — US disclosed
US-10876166-B2 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein ANDES BIOTECHNOLOGIES GLOBAL, INC. (US) 2020-12-29 — — US disclosed
US-20180340232-A1 MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN ANDES BIOTECHNOLOGIES GLOBAL INC (US) 2018-11-29 — — US disclosed
US-9903000-B2 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein ANDES BIOTECHNOLOGIES GLOBAL, INC. (US) 2018-02-27 — — US disclosed
EP-2264170-B1 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein ANDES BIOTECHNOLOGIES S A (CL) 2017-02-08 — — EP disclosed
US-20160304971-A1 MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN ANDES BIOTECHNOLOGIES SPA (CL) 2016-10-20 — — US disclosed
US-9359648-B2 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein Andes Biotechnoogies S.A. (CL) 2016-06-07 — — US disclosed
US-20150064700-A1 MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN ANDES BIOTECHNOLOGIES SPA (CL) 2015-03-05 — — US disclosed
EP-2270159-B1 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein ANDES BIOTECHNOLOGIES S A (CL) 2015-01-07 — — EP disclosed
US-8895719-B2 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein ANDES BIOTECHNOLOGIES S.A. (CL) 2014-11-25 — — US disclosed
US-20130149371-A1 MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN ANDES BIOTECHNOLIGIES S.A. (CL) 2013-06-13 — — US disclosed
US-8318686-B2 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein ANDES BIOTECHNOLOGIES S.A. (CL) 2012-11-27 — — US disclosed
EP-1625142-B1 MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN ANDES BIOTECHNOLOGIES S A (CL) 2011-04-20 — — EP disclosed
EP-2270159-A1 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein ANDES BIOTECHNOLOGIES S.A. (CL) 2011-01-05 — — EP disclosed
EP-2264170-A1 Markers for pre-cancer and cancer cells and the method to interfere with cell proliferation therein ANDES BIOTECHNOLOGIES S.A. (CL) 2010-12-22 — — EP disclosed
EP-1625142-A4 MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN BIOS CHILE I G S A (CL) 2007-04-04 — — EP disclosed
US-20060241033-A1 Markers for pre-cancer and cancer calls and the method to interfere with cell proliferation therein ANDES BIOTECHNOLOGIES SPA (CL) 2006-10-26 — — US disclosed
EP-1625142-A2 MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN Bios Chile I.G.S.A. (CL) 2006-02-15 — — EP disclosed
WO-2005001030-A2 MARKERS FOR PRE-CANCER AND CANCER CELLS AND THE METHOD TO INTERFERE WITH CELL PROLIFERATION THEREIN BIOS CHILE I.G.S.A. (CL) 2005-01-06 — — WO disclosed